Vascular risk factor detection and control may prevent Alzheimer's disease
Related Experiment Video
Updated: Jun 13, 2026

Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
1Center for Alzheimer's Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA. jcdelatorre@comcast.net
Insights
Vascular risk factors significantly contribute to cognitive decline and Alzheimer disease (AD). Early detection using non-invasive vascular screening may enable timely interventions to prevent or delay dementia onset.
Area of Science:
- Neurology
- Cardiology
- Gerontology
Background:
- The vascular hypothesis of Alzheimer disease (AD) posits that vascular risk factors (VRF) are critical in cognitive decline.
- Cardiovascular and carotid artery disease can lead to chronic brain hypoperfusion (CBH) decades before cognitive symptoms manifest.
Purpose of the Study:
- To propose a preliminary randomized clinical study for early detection of VRF in cognitively healthy individuals.
- To investigate the potential of non-invasive vascular screening to identify individuals at risk for cognitive decline due to CBH.
Main Methods:
- Screening of middle-aged individuals using carotid Doppler ultrasound, echocardiography, and ankle-brachial index.
- Utilizing non-invasive, cost-effective, and accurate office-based tools for VRF detection.
- Employing secondary screening tools like neuroimaging, neurocognitive testing, and CSF markers for confirmation.
Main Results:
- Non-invasive vascular screening can identify asymptomatic individuals at high risk for progressive cognitive decline.
- Early detection of VRF in the heart or carotid arteries allows for timely medical intervention.
- Targeted treatment based on VRF detection may prevent or slow cognitive deterioration.
Conclusions:
- Prevention-by-detection of VRF through non-invasive vascular screening offers a promising strategy for dementia prevention.
- This approach could promote healthier cognitive aging and reduce the societal burden of dementia.
- Optimizing management of cardiovascular and carotid artery disease is crucial for brain health.
Abstract:
The vascular hypothesis of Alzheimer disease (AD), first proposed by us in 1993, provides substantial evidence that suggests vascular risk factors (VRF) play a critical role in the development of cognitive decline and AD during aging. Cardiovascular and carotid artery disease, two major risk factors to AD, can conspire or independently induce chronic brain hypoperfusion (CBH) decades before any symptoms of cognitive impairment are expressed. The pathologic construct linking CBH to cognitive impairment and AD remains unclear but evidence shows that it may provide an opportunity to intervene in the prevention or delay of dementia onset. A preliminary randomized clinical study in cognitively healthy middle age individuals to undergo screening using carotid Doppler ultrasound, echocardiography and ankle-brachial index is proposed. These office tools are non-invasive, cost-effective, easily applied in one session and relatively accurate procedures with no inherent harmful effects. More importantly, ultrasound can help identify asymptomatic patients most likely to develop progressive cognitive decline due to persistent CBH secondary to progressive cardiovascular or carotid artery pathology. When these VRF are detected within the heart or carotid arteries, optimal medical treatment or management may be indicated to prevent or slow down further disease progression that fosters cognitive deterioration generated from such conditions. Secondary screening tools such as neuroimaging, neurocognitive testing and CSF markers may be used to confirm ultrasound findings. Prevention-by-detection of VRF and target treatment, if found effective, could significantly promote healthier mental and physical aging and lessen the socio-economic calamity anticipated from the growing prevalence of dementia.
Related Concept Videos
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
Atherosclerosis III: Management
